Furin inhibitor D6R suppresses epithelial-mesenchymal transition in SW1990 and PaTu8988 cells via the Hippo-YAP signaling pathway

Zhou,Meng; Zhang,Youli; Wei,Hong; He,Junbo; Wang,Dawei; Chen,Baoding; Zeng,Jian; Gong,Aihua; Xu,Min

doi:10.3892/ol.2017.7672

Furin inhibitor D6R suppresses epithelial-mesenchymal transition in SW1990 and PaTu8988 cells via the Hippo-YAP signaling pathway

Authors:
- Meng Zhou
- Youli Zhang
- Hong Wei
- Junbo He
- Dawei Wang
- Baoding Chen
- Jian Zeng
- Aihua Gong
- Min Xu
View Affiliations

Affiliations: Department of Gastroenterology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China, Department of Ultrasound Diagnosis, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China, Department of Cell Biology, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China
Published online on: December 20, 2017 https://doi.org/10.3892/ol.2017.7672
Pages: 3192-3196

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hexa-D-arginine (D6R), an inhibitor of furin, has potential therapeutic applications in different types of human tumor. However, the function of D6R in targeting pancreatic cancer cells remains to be elucidated. In the present study, the proliferation, invasion and migration abilities of SW1990 and PaTu8988 cells were examined using a Cell Counting Kit‑8, and Transwell and wound healing assays. Subsequently, the expression of proteins associated with epithelial‑mesenchymal transition (EMT) and the Hippo‑yes‑associated protein (YAP) pathway were detected using western blot analysis. It was revealed that D6R significantly inhibited the proliferation, migration and invasion abilities of SW1990 and PaTu8988 cells. Additionally, D6R led to the upregulation of E‑cadherin (an epithelial marker), and the downregulation of N‑cadherin and vimentin (mesenchymal markers) in SW1990 and PaTu8988 cells. Furthermore, the results of the present study revealed that D6R significantly affected the YAP phosphorylation level and the total YAP protein level, indicating that D6R was functionally involved in the Hippo‑YAP signaling pathway. It has been suggested that D6R‑suppressed EMT in SW1990 and PaTu8988 cells may occur via the Hippo‑YAP pathway and that it may be a feasible drug to ameliorate the malignant phenotype of SW1990 and PaTu8988 cells.

View Figures

View References

1	Bassi DE, Mahloogi H and Klein-Szanto AJ: The proprotein convertases furin and PACE4 play a significant role in tumor progression. Mol Carcinog. 28:63–69. 2000. View Article : Google Scholar : PubMed/NCBI
2	Pei D and Weiss SJ: Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature. 375:244–247. 1995. View Article : Google Scholar : PubMed/NCBI
3	Shiryaev SA, Remacle AG, Ratnikov BI, Nelson NA, Savinov AY, Wei G, Bottini M, Rega MF, Parent A, Desjardins R, et al: Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem. 282:20847–20853. 2007. View Article : Google Scholar : PubMed/NCBI
4	Becker GL, Lu Y, Hardes K, Strehlow B, Levesque C, Lindberg I, Sandvig K, Bakowsky U, Day R, Garten W and Steinmetzer T: Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases. J Biol Chem. 287:21992–22003. 2012. View Article : Google Scholar : PubMed/NCBI
5	Thomas G: Furin at the cutting edge: From protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol. 3:753–766. 2002. View Article : Google Scholar : PubMed/NCBI
6	Dubois CM, Blanchette F, Laprise MH, Leduc R, Grondin F and Seidah NG: Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme. Am J Pathol. 158:305–316. 2001. View Article : Google Scholar : PubMed/NCBI
7	Yana I and Weiss SJ: Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Biol Cell. 11:2387–2401. 2000. View Article : Google Scholar : PubMed/NCBI
8	López de Cicco R, Watson JC, Bassi DE, Litwin S and Klein-Szanto AJ: Simultaneous expression of furin and vascular endothelial growth factor in human oral tongue squamous cell carcinoma progression. Clin Cancer Res. 10:4480–4488. 2004. View Article : Google Scholar : PubMed/NCBI
9	Pang YJ, Tan XJ, Li DM, Zheng ZH, Lei RX and Peng XM: Therapeutic potential of furin inhibitors for the chronic infection of hepatitis B virus. Liver Int. 33:1230–1238. 2013. View Article : Google Scholar : PubMed/NCBI
10	Bassi DE, Lopez De Cicco R, Mahloogi H, Zucker S, Thomas G and Klein-Szanto AJ: Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells. Proc Natl Acad Sci USA. 98:pp. 10326–10331. 2001; View Article : Google Scholar : PubMed/NCBI
11	Coppola JM, Bhojani MS, Ross BD and Rehemtulla A: A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia. 10:363–370. 2008. View Article : Google Scholar : PubMed/NCBI
12	Cameron A, Appel J, Houghten RA and Lindberg I: Polyarginines are potent furin inhibitors. J Biol Chem. 275:36741–36749. 2000. View Article : Google Scholar : PubMed/NCBI
13	Komiyama T, Swanson JA and Fuller RS: Protection from anthrax toxin-mediated killing of macrophages by the combined effects of furin inhibitors and chloroquine. Antimicrob Agents Chemother. 49:3875–3882. 2005. View Article : Google Scholar : PubMed/NCBI
14	Ozden S, Lucas-Hourani M, Ceccaldi PE, Basak A, Valentine M, Benjannet S, Hamelin J, Jacob Y, Mamchaoui K, Mouly V, et al: Inhibition of Chikungunya virus infection in cultured human muscle cells by furin inhibitors: Impairment of the maturation of the E2 surface glycoprotein. J Biol Chem. 283:21899–21908. 2008. View Article : Google Scholar : PubMed/NCBI
15	Sarac MS, Cameron A and Lindberg I: The furin inhibitor hexa-D-arginine blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo. Infect Immun. 70:7136–7139. 2002. View Article : Google Scholar : PubMed/NCBI
16	Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI
17	Reubi JC: Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 24:389–427. 2003. View Article : Google Scholar : PubMed/NCBI
18	Khatib AM, Siegfried G, Prat A, Luis J, Chrétien M, Metrakos P and Seidah NG: Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: Importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions. J Biol Chem. 276:30686–30693. 2001. View Article : Google Scholar : PubMed/NCBI
19	Longuespée R, Couture F, Levesque C, Kwiatkowska A, Desjardins R, Gagnon S, Vergara D, Maffia M, Fournier I, Salzet M and Day R: Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target. Transl Oncol. pii:S1936–5233. 2014.
20	Mercapide J, Lopez De Cicco R, Bassi DE, Castresana JS, Thomas G and Klein-Szanto AJ: Inhibition of furin-mediated processing results in suppression of astrocytoma cell growth and invasiveness. Clin Cancer Res. 8:1740–1746. 2002.PubMed/NCBI
21	Maquoi E, Noël A, Frankenne F, Angliker H, Murphy G and Foidart JM: Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor. FEBS Lett. 424:262–266. 1998. View Article : Google Scholar : PubMed/NCBI
22	Angliker H: Synthesis of tight binding inhibitors and their action on the proprotein-processing enzyme furin. J Med Chem. 38:4014–4018. 1995. View Article : Google Scholar : PubMed/NCBI
23	Bartholin L: Pancreatic cancer and the tumor microenvironment: Mesenchyme's role in pancreatic carcinogenesisPancreatic Cancer and Tumor Microenvironment. Grippo PJ and Munshi HG: Trivandrum (India): 2012
24	Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, Murter C, Hong SM, Koorstra JB, Rajeshkumar NV, He X, et al: Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst. 102:340–351. 2010. View Article : Google Scholar : PubMed/NCBI
25	Hotz B, Arndt M, Dullat S, Bhargava S, Buhr HJ and Hotz HG: Epithelial to mesenchymal transition: Expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res. 13:4769–4776. 2007. View Article : Google Scholar : PubMed/NCBI
26	Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ and Choi W: Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 69:5820–5828. 2009. View Article : Google Scholar : PubMed/NCBI